scholarly journals DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis

2017 ◽  
Vol 8 (17) ◽  
pp. 3585-3591 ◽  
Author(s):  
Chenzi Zhang ◽  
Wenjun Yu ◽  
Lin Wang ◽  
Mingna Zhao ◽  
Qiaomei Guo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Methylation ◽  
Bronchoalveolar Lavage ◽  
Cancer Diagnosis ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Methylation Analysis ◽  
Lung Cancer Diagnosis ◽  
Dna Methylation Analysis

scholarly journals Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e11528
Author(s):  
Wen-Jun Zhu ◽  
Bo-Jiang Chen ◽  
Ying-Ying Zhu ◽  
Ling Sun ◽  
Yu-Chen Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Roc Curve ◽  
Lung Diseases ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Background MicroRNA-30a (miRNA-30a) levels have been shown to increase in the plasma of lung cancer patients. Herein, we evaluated the miRNA-30a levels in the bronchoalveolar lavage fluid (BALF) of lung cancer patients as a potential biomarker for lung cancer diagnosis. Methods BALF miRNA-30a expression of 174 subjects was quantified using quantitative real-time reverse transcription-polymerase chain reaction and compared between lung cancer patients and control patients with benign lung diseases. Moreover, its diagnostic value was evaluated by performing receiver operating characteristic (ROC) curve analysis. Results The relative BALF miRNA-30a expression was significantly higher in the lung cancer patients than in the controls (0.74 ±  0.55 versus 0.07 ±  0.48, respectively, p < 0.001) as well as in lung cancer patients with stage I–IIA disease than in those with stage IIB–IV disease (0.98 ±  0.64 versus 0.66 ±  0.54, respectively, p < 0.05). Additionally, miRNA-30a distinguished benign lung diseases from lung cancers, with an area under the ROC curve (AUC) of 0.822. ROC analysis also revealed an AUC of 0.875 for the Youden index-based optimal cut-off points for stage I–IIA adenocarcinoma. Thus, increased miRNA-30a levels in BALF may be a useful biomarker for non-small-cell lung cancer diagnosis.

Detection of K-ras Oncogene Mutations in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis

1995 ◽  
Vol 87 (14) ◽  
pp. 1056-1060 ◽  
Author(s):  
N. E. Mills ◽  
C. L. Fishman ◽  
J. Scholes ◽  
S. E. Anderson ◽  
W. N. Rom ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Cancer Diagnosis ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Ras Oncogene ◽  
Lung Cancer Diagnosis

scholarly journals DNA methylation analysis: a powerful new tool for lung cancer diagnosis

Oncogene ◽  
2002 ◽  
Vol 21 (35) ◽  
pp. 5450-5461 ◽  
Author(s):  
Jeffrey A Tsou ◽  
Jeffrey A Hagen ◽  
Catherine L Carpenter ◽  
Ite A Laird-Offringa
Keyword(s):  
Lung Cancer ◽  
Dna Methylation ◽  
Cancer Diagnosis ◽  
Methylation Analysis ◽  
Lung Cancer Diagnosis ◽  
Dna Methylation Analysis

scholarly journals Evaluation of VEGF-C and Tumor Markers in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis

2013 ◽  
Vol 3 (1) ◽  
Author(s):  
Chao Cao ◽  
Zhong-Bo Chen ◽  
Shi-Fang Sun ◽  
Yi-Ming Yu ◽  
Qun-Li Ding ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Tumor Markers ◽  
Cancer Diagnosis ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Diagnosis

scholarly journals Diagnosis of pulmonary nodules by DNA methylation analysis in bronchoalveolar lavage fluids

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Lei Li ◽  
Zhujia Ye ◽  
Sai Yang ◽  
Hao Yang ◽  
Jing Jin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Methylation ◽  
Bronchoalveolar Lavage ◽  
Pulmonary Nodules ◽  
Squamous Carcinoma ◽  
Lavage Fluid ◽  
Smoking History ◽  
Lung Cancer Diagnosis ◽  
Auc Value ◽  
Validation Set

Abstract Background Lung cancer is the leading cause of cancer-related mortality. The alteration of DNA methylation plays a major role in the development of lung cancer. Methylation biomarkers become a possible method for lung cancer diagnosis. Results We identified eleven lung cancer-specific methylation markers (CDO1, GSHR, HOXA11, HOXB4-1, HOXB4-2, HOXB4-3, HOXB4-4, LHX9, MIR196A1, PTGER4-1, and PTGER4-2), which could differentiate benign and malignant pulmonary nodules. The methylation levels of these markers are significantly higher in malignant tissues. In bronchoalveolar lavage fluid (BALF) samples, the methylation signals maintain the same differential trend as in tissues. An optimal 5-marker model for pulmonary nodule diagnosis (malignant vs. benign) was developed from all possible combinations of the eleven markers. In the test set (57 tissue and 71 BALF samples), the area under curve (AUC) value achieves 0.93, and the overall sensitivity is 82% at the specificity of 91%. In an independent validation set (111 BALF samples), the AUC is 0.82 with a specificity of 82% and a sensitivity of 70%. Conclusions This model can differentiate pulmonary adenocarcinoma and squamous carcinoma from benign diseases, especially for infection, inflammation, and tuberculosis. The model’s performance is not affected by gender, age, smoking history, or the solid components of nodules.

scholarly journals Diagnostic Utility of Adenosine Deaminase in Serum and Bronchoalveolar Lavage Fluid for Screening Lung Cancer in Western Iran

2013 ◽  
Vol 32 (2) ◽  
pp. 109-115 ◽  
Author(s):  
Bahram Nikkhoo ◽  
Naseh Sigari ◽  
Bayazid Ghaderi ◽  
Abdolrahim Afkhamzadeh ◽  
Namam-Ali Azadi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adenosine Deaminase ◽  
Cancer Diagnosis ◽  
Bronchoalveolar Lavage Fluid ◽  
Screening Tool ◽  
Lavage Fluid ◽  
Control Group ◽  
Blood Samples ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Summary Background: This study aimed to determine adenosine deaminase (ADA) activity as a possible screening tool in lung cancer patients. Methods: Blood samples were collected from 30 subjects with positive pathological tests and 62 patients with negative pathological tests as a control group. The enzymatic activity of total ADA and its isoenzymes was determined. Results: tADA and ADA2 isoenzyme activity was significantly higher in cancerous patients compared to benign controls in serum and BAL fluid. Using a cut-off level of respectively 35.22 U/L and 31.80 U/L for BAL total ADA and ADA2, sensitivity and specificity were 100% and 81% for total ADA and 95% and 98% for ADA2. Conclusions: Adenosine deaminase may play important roles in the pathophysiology of lung cancer and because of its might be considered as a useful screening tool among the other markers in lung cancer diagnosis.

Sign in / Sign up

Export Citation Format

Share Document